Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 13/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 8/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734296 | 0.88 | OPRM1 (0.50) | OPRM1OPRL1OGFRL1KDM4E | |
| SCHEMBL733086 | 0.85 | OPRM1 (0.45) | OPRM1OPRL1OGFRL1KIF11 | |
| SCHEMBL734664 | 0.83 | KIF11 (0.37) | OPRM1OGFRL1KIF11KDM4ECRHBP | |
| SCHEMBL734169 | 0.82 | OPRM1 (0.57) | OPRM1OPRL1OGFRL1OPRD1OPRK1 | |
| SCHEMBL734144 | 0.80 | OPRM1 (0.43) | OPRM1OPRL1OGFRL1OPRD1OPRK1 | |
| SCHEMBL734846 | 0.78 | KDM4E (0.33) | KIF11KDM4ECRHBPCRHR2 | |
| SCHEMBL735507 | 0.76 | OPRM1 (0.57) | OPRM1OPRL1OGFRL1OPRD1OPRK1 | |
| SCHEMBL734668 | 0.76 | OPRM1 (0.45) | OPRM1OPRL1OGFRL1OPRD1OPRK1 | |
| SCHEMBL733908 | 0.76 | OPRL1 (0.47) | OPRM1OPRL1OGFRL1KIF11 | |
| SCHEMBL734100 | 0.73 | OPRM1 (0.40) | OPRM1OPRL1OGFRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044016-B1 | 4-HETEROARYL-SUBSTITUTED 1-AMINOCYCLOHEXANE-1-AND CYCLOHEXENE-1-DERIVATIVES HAVING EFFECTS ON THE OPIOD RECEPTOR SYSTEM | GRUENENTHAL GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-8138187-B2 | Substituted heteroaryl derivatives | GRUENENTHAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | GRUNENTHAL GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009986-A1 | SUBSTITUTED HETEROARYL DERIVATIVES | CYP3A43, HMGCR, ABCG2 | OPRM1 1029/4885OPRL1 1562/4885OGFRL1 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.